
![]()
| No. | Facility type | Product | Audit period | Chiyoda’s position |
|---|---|---|---|---|
| 1 | Commercial facility |
API | FDA (CDER) |
EPC |
| 2 | Commercial facility |
API | FDA (CDER) |
EPCV |
| 3 | Commercial facility |
API intermediate |
FDA (CDER) |
Cn (Witness) |
| 4 | Commercial facility |
API | FDA (CDER) |
Cn (Witness) |
| 5 | Commercial facility |
API | FDA (CDER) |
EPCV (Witness) |
| 6 | Commercial facility |
API | FDA (CDER) |
EPCV (Witness) |
| 7 | Commercial facility |
Solid dosage |
FDA(CDER)/ EU(EMEA) |
Cn (Witness) |
| 8 | Clinical facility |
Solid dosage |
FDA(CDER)/ EU(EMEA) |
V |
| 9 | Commercial facility |
Injection | FDA(CDER)/ EU(EMEA) |
EPCV |
| 10 | Commercial facility |
Injection | FDA (CDER) |
V |
| 11 | Commercial facility |
API | FDA (CDER) |
Cn (Witness) |
| 12 | Commercial facility |
API intermediate |
FDA (CDER) |
Cn (Witness) |
| 13 | Commercial facility |
Dosage | FDA (CDER) |
V, (Witness) |
| 14 | Clinical facility |
Dosage | EU (EMEA) |
Cn |
| 15 | Commercial facility |
Dosage | FDA (CDER) |
V, (Witness) |
| E: | Engineering | P: | Procurement | C: | Construction |
|---|---|---|---|---|---|
| V: | Validation | Cn: | Consulting |